| 產(chǎn)品名稱 |
KMC8.8 |
| 商品貨號 |
B164924 |
| Organism |
Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts with mouse CD9 (expressed by bone marrow stromal cells, megakaryocytes, platelets, myeloid cells and subpopulations of mature lymphocytes. |
| Derivation |
Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against mouse CD9 |
| Cellular Products |
immunoglobulin; monoclonal antibody; against mouse CD9 |
| Tumorigenic |
Yes |
| Effects |
Yes, produces only modest amounts of ascites in SCID mice because it usually fatal within two weeks of inoculation |
| Comments |
Animals were immunized with BMS2 murine bone marrow stromal cells. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts with mouse CD9 (expressed by bone marrow stromal cells, megakaryocytes, platelets, myeloid cells and subpopulations of mature lymphocytes. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Isotype |
IgG2a |
| Name of Depositor |
PW Kincade |
| Deposited As |
rat (B cell); mouse (myeloma) |
| References |
Oritani K, et al. Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures. Blood 87: 2252-2261, 1996. PubMed: 8630385
|
